TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20609025

Group type: EXPERIMENTAL
Intervention: Resilon filled with immediate post space preparation leaving 5 mm of apical filling
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Resilon filled with delayed post space preparation for 1 week leaving 5 mm of material apically
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Resilon filled with immediate post space preparation leaving 3 mm of material apically
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Resilon filled with delayed post space preparation for 1 week leaving 3 mm of material apically
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (root canals not filled)
Number of subjects: 150
Study: 17591530

Group type: EXPERIMENTAL
Intervention: Interdialytic weight gain (IDWG)
Number of subjects: 442
Study: 16046102

Group type: EXPERIMENTAL
Intervention: 1600 mg SAMe (pharmaceutical dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg SAMe (nutraceutical dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12122721

Group type: EXPERIMENTAL
Intervention: Somatostatin 14 (S-14) infusion at a dose of 6 mg/24 h (days 1-6) and 3 mg/24 h (day 7)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 75
Study: 11016491

Group type: EXPERIMENTAL
Intervention: Dynamic cardiomyoplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 0
Study: 8646833

Group type: EXPERIMENTAL
Intervention: DIABETES expert system for decision support
Number of subjects: 600

Group type: COMPARATOR
Intervention: Medical doctors' responses
Number of subjects: 600
Study: 1498074

Group type: EXPERIMENTAL
Intervention: Sequential MTX (300 mg/m2) and FU (900 mg/m2) with leucovorin rescue
Number of subjects: 172

Group type: COMPARATOR
Intervention: FU alone (450 mg/m2/d for five days)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Sequential MTX/FU
Number of subjects: 172

Group type: COMPARATOR
Intervention: FU alone
Number of subjects: 172

Group type: COMPARATOR
Intervention: Sequential MTX/FU and FU alone
Number of subjects: 172
Study: 6395272

Group type: EXPERIMENTAL
Intervention: Cefonicid
Number of subjects: 1060
Study: 30943313

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 22
Study: 28065207

Group type: EXPERIMENTAL
Intervention: Text messaging follow-up (40 participants)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional telephone follow-up (78 participants)
Number of subjects: 118
Study: 26871794

Group type: EXPERIMENTAL
Intervention: F4/AS01B_2 group (N=64)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: F4/AS01B_3 group (N=62)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (N=64)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: F4/AS01B
Number of subjects: 186
Study: 25135040

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation (TVNS) applied to the auricular concha bilaterally for 35min using 2Hz/100Hz bursts with individually maximal but non-painful intensity
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (no stimulation)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation (TVNS)
Number of subjects: 22
Study: 22314130

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 636

Group type: COMPARATOR
Intervention: Surgical repair
Number of subjects: 636
Study: 19171289

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio
Number of subjects: 155
Study: 17198906

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Aliskiren monotherapy
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Aliskiren and valsartan in combination
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Valsartan/hydrochlorothiazide (160/12.5 mg)
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1123
Study: 16246660

Group type: EXPERIMENTAL
Intervention: LNG‐20 microg IUS
Number of subjects: 320

Group type: COMPARATOR
Intervention: Cu T380A IUD
Number of subjects: 320
Study: 11565518

Group type: EXPERIMENTAL
Intervention: Losartan (50 to 100 mg once daily)
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study: 9280384

Group type: EXPERIMENTAL
Intervention: Behavioral Skills Training program (BST; Wurtele, 1986)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control program
Number of subjects: 406
Study: 8336206

Group type: EXPERIMENTAL
Intervention: 7500 micrograms RE (Group B)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 60,000 micrograms RE (Group C)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Peanut oil only (Group A)
Number of subjects: 149
Study: 3464712

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous diazepam
Number of subjects: 50
Study: 2732067

Group type: EXPERIMENTAL
Intervention: 3Rs and HBP curriculum with home blood pressure measurement component
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: 3Rs and HBP curriculum without home blood pressure measurement component
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1204
Study: 31816193

Group type: EXPERIMENTAL
Intervention: Ultra-rapid lispro (URLi)
Number of subjects: 31

Group type: COMPARATOR
Intervention: lispro (Humalog®)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ultra-rapid lispro (URLi) and lispro (Humalog®)
Number of subjects: 31
Study: 31154239

Group type: EXPERIMENTAL
Intervention: Conventional group therapy plus an additional 10 hours of group therapy focusing on stimulant use
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional group therapy only (treatment as usual)
Number of subjects: 108
Study: 28334419

Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT) with good/excellent cosmetic outcomes
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT) with fair/poor cosmetic outcomes
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: BCCT.core software evaluation
Number of subjects: 128
Study: 25033034

Group type: EXPERIMENTAL
Intervention: CogSMART intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Additional supported employment sessions
Number of subjects: 50
Study: 23490168

Group type: EXPERIMENTAL
Intervention: Pre‐Seed personal lubricant
Number of subjects: 22

Group type: COMPARATOR
Intervention: No lubricant (control)
Number of subjects: 22
Study: 21464685

Group type: EXPERIMENTAL
Intervention: Intervention group (12 weekly healthy lifestyle sessions based on the Diabetes Prevention Program curriculum)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait control group
Number of subjects: 45
Study: 18317875

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (ARB)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no ARB)
Number of subjects: 13
Study: 16099450

Group type: EXPERIMENTAL
Intervention: Home remediation
Number of subjects: 98
Study: 15519938

Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage (SSBM) for ten minutes for seven consecutive evenings
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage (SSBM)
Number of subjects: 102
Study: 11764128

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose Plus with Z‐100
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% NaOCl treatment after phosphoric acid treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cavities treated without NaOCl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cavities treated with NaOCl
Number of subjects: 20
Study: 9284856

Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8329783

Group type: EXPERIMENTAL
Intervention: 1 mg with 6‐minute lockout (n = 10)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2 mg with 12‐minute lockout (n = 12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2 mg with 20‐minute lockout (n = 12)
Number of subjects: 34

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 34
Study: 3771502

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31578100

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA administered by a specialist nurse
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA with removal of the positive stopping rule
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Combination of onabotulinumtoxinA scenarios
Number of subjects: 633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study: 31176028

Group type: EXPERIMENTAL
Intervention: Scheduled-dose multimodal analgesia with minimal opiate supply (group A)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Scheduled-dose multimodal analgesia with traditional opiate supply (group B)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Traditional pro re nata (as needed) opiate regimen alone (group C)
Number of subjects: 235
Study: 28961661

Group type: EXPERIMENTAL
Intervention: Blister packing medications (BP)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Dispense as usual (Control)
Number of subjects: 243
Study: 26165588

Group type: COMPARATOR
Intervention: Baseline prostate atrophy (graded as absent, mild, or moderate/marked)
Number of subjects: 3084

Group type: COMPARATOR
Intervention: Mild atrophy
Number of subjects: 3084

Group type: COMPARATOR
Intervention: Moderate/marked atrophy
Number of subjects: 3084

Group type: COMPARATOR
Intervention: Baseline prostate atrophy
Number of subjects: 3084
Study: 22781166

Group type: EXPERIMENTAL
Intervention: Full cognitive behaviour therapy (CBT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Partial therapy (attending sessions but not proceeding beyond engagement and assessment strategies)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No therapy (not attending sessions)
Number of subjects: 92
Study: 21780853

Group type: EXPERIMENTAL
Intervention: Repaglinide plus metformin 1 mg/500 mg t.i.d. (maximum dose, 4 mg/500 mg t.i.d.)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Repaglinide 1 mg t.i.d. (maximum dose, 4 mg t.i.d.)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Repaglinide plus metformin
Number of subjects: 432

Group type: COMPARATOR
Intervention: Repaglinide
Number of subjects: 432
Study: 18582181

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.4 mg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.8 mg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate (1.5 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17090999

Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 12646783

Group type: EXPERIMENTAL
Intervention: Acute inflammatory events (IE) in the previous 30 days
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Acute inflammatory events (IE) in the previous 7 days
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Acute inflammatory events (IE) stratified for atherothrombotic stroke
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Acute inflammatory events (IE) stratified for cardioembolic stroke
Number of subjects: 293
Study: 11388814

Group type: EXPERIMENTAL
Intervention: Optimal CPAP (n = 29)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham CPAP (n = 25)
Number of subjects: 55
Study: 9094765

Group type: EXPERIMENTAL
Intervention: 15-week aerobic activity program, exercised 4 days per week
Number of subjects: 25

Group type: COMPARATOR
Intervention: Regular physical education program (control group)
Number of subjects: 25
Study: 8325074

Group type: EXPERIMENTAL
Intervention: Hygroscopic heat and moisture exchangers (groups 2 and 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrophobic heat and moisture exchanger (group 1)
Number of subjects: 0
Study: 2880689

Group type: EXPERIMENTAL
Intervention: Indenolol (30 to 120 mg)
Number of subjects: 19
Study: 30889454

Group type: EXPERIMENTAL
Intervention: CurQfen® (curcumin formulated with fenugreek soluble fiber) at 500mg/d for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (fenugreek soluble fiber)
Number of subjects: 22
Study: 28397533

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy adherence assessment
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Socioeconomic factors (income and ethnicity)
Number of subjects: 242
Study: 25990260

Group type: COMPARATOR
Intervention: 980-nm laser
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1470-nm laser
Number of subjects: 96
Study: 24475556

Group type: EXPERIMENTAL
Intervention: 0.5% gentian violet paint local application
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 400
Study: 25155813

Group type: EXPERIMENTAL
Intervention: PHQ-9
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: BDI-II
Number of subjects: 172

Group type: COMPARATOR
Intervention: PHQ-9 and BDI-II
Number of subjects: 172
Study: 18426627

Group type: EXPERIMENTAL
Intervention: Preoperative oral administration of ramosetron 0.1 mg (Group C)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Single prophylactic intravenous injection of ramosetron 0.1 mg (Group B)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No prophylactic antiemetics (Group A)
Number of subjects: 240
Study: 17175489

Group type: EXPERIMENTAL
Intervention: Cetrorelix 0.2 mg/day (Group 1)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cetrorelix 0.15 mg/day (Group 2)
Number of subjects: 58
Study: 14561020

Group type: EXPERIMENTAL
Intervention: HandiHaler (tiotropium 18 microg daily)
Number of subjects: 151

Group type: COMPARATOR
Intervention: MDI (ipratropium 20 microg, two actuations q.i.d.)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: HandiHaler
Number of subjects: 151

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 151
Study: 11127249

Group type: EXPERIMENTAL
Intervention: Quinine (oral dose)
Number of subjects: 17
Study: 8865956

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU three times a week)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Biological markers of alcohol consumption
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Carbohydrate deficient transferrin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Gamma‐glutamyl transpeptidase
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Beta‐hexosaminidase
Number of subjects: 59
Study: 1893708

Group type: EXPERIMENTAL
Intervention: TCu 380A
Number of subjects: 2845

Group type: EXPERIMENTAL
Intervention: LLD
Number of subjects: 2845

Group type: EXPERIMENTAL
Intervention: MLCu 375
Number of subjects: 2845
Study: 6382932

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 4

Group type: COMPARATOR
Intervention: Ionic media
Number of subjects: 4
Study: 31029516

Group type: EXPERIMENTAL
Intervention: Dukoral® oral cholera vaccine (administered at baseline and day 14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dukoral® oral cholera vaccine (administered at baseline and day 14) in P/CNI group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dukoral® oral cholera vaccine (administered at baseline and day 14) in P/MMF group
Number of subjects: 30
Study: 28614627

Group type: EXPERIMENTAL
Intervention: Multimodal cachexia intervention (n‐3 polyunsaturated fatty acid nutritional supplements, exercise, and anti‐inflammatory medication: celecoxib)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Multimodal cachexia intervention
Number of subjects: 46
Study: 25848235

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Respiratory training (breathing group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Social interaction (control group)
Number of subjects: 102
Study: 23718152

Group type: EXPERIMENTAL
Intervention: Targeted decolonization (screening, isolation, and decolonization of MRSA carriers)
Number of subjects: 74256

Group type: EXPERIMENTAL
Intervention: Universal decolonization (no screening, and decolonization of all patients)
Number of subjects: 74256

Group type: COMPARATOR
Intervention: Screening and isolation (MRSA screening and isolation)
Number of subjects: 74256
Study: 22231004

Group type: EXPERIMENTAL
Intervention: Toothbrushing with 0.12% chlorhexidine gluconate (Periogard®) mouthrinses twice a week
Number of subjects: 34

Group type: COMPARATOR
Intervention: Toothbrushing with fluoride dentifrice (control)
Number of subjects: 34
Study: 19124701

Group type: EXPERIMENTAL
Intervention: Single physician e-mail intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 190
Study: 17876019

Group type: COMPARATOR
Intervention: Combined exercise training
Number of subjects: 251

Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Blood pressure and lipid values
Number of subjects: 251
Study: 15523457

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler ultrasound testing in patients with migraine-related dizziness
Number of subjects: 19

Group type: COMPARATOR
Intervention: Transcranial Doppler ultrasound testing in control patients (no history of migraine or dizziness)
Number of subjects: 19
Study: 11831621

Group type: EXPERIMENTAL
Intervention: C-reactive protein measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Successful treatment strategies for atheroma
Number of subjects: 0
Study: 9758029

Group type: EXPERIMENTAL
Intervention: SUPPORT intervention (n=386): specially trained nurses providing extra time to explain prognoses and treatments
Number of subjects: 717

Group type: COMPARATOR
Intervention: Usual care (n=331)
Number of subjects: 717
Study: 8641505

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a) treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: No preoperative medical treatment
Number of subjects: 41
Study: 2149913

Group type: EXPERIMENTAL
Intervention: Desogestrel (DG)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Gestodene (GD)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 54
Study: 6795050

Group type: EXPERIMENTAL
Intervention: Acute pentagastrin injection in normal male subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower doses of pentagastrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulation of gastrin secretion by a protein test meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intragastric administration of a calcium chloride solution
Number of subjects: 0
Study: 31558323

Group type: EXPERIMENTAL
Intervention: SCP‐A (web‐based survivorship care plan application)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study: 30776572

Group type: EXPERIMENTAL
Intervention: Modified Cigarette Evaluation Questionnaire (mCEQ) Satisfaction subscale
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Modified Cigarette Evaluation Questionnaire (mCEQ) Enjoyment of Respiratory Tract Sensations subscale
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Cigarette Purchase Task (CPT) Elasticity index
Number of subjects: 169
Study: 29065142

Group type: EXPERIMENTAL
Intervention: MVA-B boost (fourth dose)
Number of subjects: 13
Study: 26835542

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 24912179

Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22718547

Group type: EXPERIMENTAL
Intervention: 0.25mg pramipexole
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 0.5mg clonazepam
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 20145345

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/day) with clopidogrel (75 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/day) alone (placebo)
Number of subjects: 20
Study: 17919378

Group type: EXPERIMENTAL
Intervention: Cattle encephalon glycoside and ignotin injection (20 ml after induction of anesthesia)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study: 15673424

Group type: EXPERIMENTAL
Intervention: Oral sucrose solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 12540322

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9447396

Group type: EXPERIMENTAL
Intervention: Hemoccult II screening test
Number of subjects: 0
Study: 7963387

Group type: EXPERIMENTAL
Intervention: Interpleural block (IPB) with 10 ml of 1% lidocaine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Epidural block (EB) with 10 ml of 1% lidocaine
Number of subjects: 17
Study: 3298360

Group type: EXPERIMENTAL
Intervention: Intravenous APSAC, 30 mg (n = 16)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 40
Study: 31996139

Group type: EXPERIMENTAL
Intervention: Trendelenburg position (20°) for 24 hours postoperatively
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard postoperative care in supine head up position
Number of subjects: 101
Study: 29371383

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 14 days on/off
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 28 days on/off
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo 14 days on/off
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo 28 days on/off
Number of subjects: 416
Study: 27629372

Group type: EXPERIMENTAL
Intervention: Resective surgery combined with corpus callosotomy (CCT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Exclusively resective surgery
Number of subjects: 68

Group type: COMPARATOR
Intervention: Medicine (medicine group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Resective surgery combined with CCT
Number of subjects: 68